RecruitingNot applicableNCT06586710
Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Meyer Children's Hospital IRCCS
- Principal Investigator
- Carmela ErrichielloMeyer Children's Hospital IRCCS, Florence, Italy
- Intervention
- Assessment activation of interferon pathway(other)
- Enrollment
- 60 target
- Eligibility
- 17 years · All sexes
- Timeline
- 2023 – 2025
Study locations (3)
- Meyer Children's Hospital IRCCS, Florence, Italy
- IRCCS Gianna Gaslini, Genova, Italy
- IRCCS Humanitas Research Hospital, Rozzano, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06586710 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGPHASE2NCT05538208The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE3NCT05835310An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsAstraZeneca
- RECRUITINGPHASE2NCT05039619A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsHoffmann-La Roche
- ACTIVE NOT RECRUITINGPHASE2NCT04179032Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)GlaxoSmithKline